Company / Working Capital
ADMA Biologics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$397.0M
FY2025
5-year range
$178.4M / $397.0M
FY2021-FY2025
Trend
+43.9%
vs FY2024
Sector context
#109 of 213
Health Care
What the data says
At $397M, ADMA Biologics, Inc.'s working capital ranks #109 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $10M in FY2016 to $397M in FY2025.
Based on SEC 10-K filings.
$397M in FY2025 with a 5-year CAGR of +24.3%.
Improved from $207M to $397M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +19.8%
- 5-Year CAGR
- +24.3%
- 10-Year CAGR
- -
Sector benchmark
#109 of 213 in Health CareTop 51% of 213This company $397.0M Sector average $934.6M
▼
-57.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +24.3%, indicating consistent growth.
- In FY2025, working capital increased 43.9% year-over-year.
- Ranks #109 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $397.0M | +43.9% |
| FY2024 | $275.9M | +33.1% |
| FY2023 | $207.2M | -10.4% |
| FY2022 | $231.1M | +29.6% |
| FY2021 | $178.4M | +33.3% |
| FY2020 | $133.8M | +86.4% |
| FY2019 | $71.8M | +105.7% |
| FY2018 | $34.9M | -35.0% |
| FY2017 | $53.7M | +414.9% |
| FY2016 | $10.4M | -38.9% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026